SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 232 filers reported holding SAGE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $457,000 | +15.1% | 11,674 | -5.1% | 0.00% | +33.3% |
Q2 2022 | $397,000 | -0.3% | 12,303 | +2.4% | 0.00% | +50.0% |
Q1 2022 | $398,000 | -21.8% | 12,019 | +0.4% | 0.00% | -33.3% |
Q4 2021 | $509,000 | -78.3% | 11,976 | -77.4% | 0.00% | -78.6% |
Q3 2021 | $2,348,000 | -2.4% | 52,994 | +25.1% | 0.01% | 0.0% |
Q2 2021 | $2,406,000 | -15.9% | 42,353 | +10.8% | 0.01% | -26.3% |
Q1 2021 | $2,862,000 | +2.0% | 38,234 | +17.8% | 0.02% | +5.6% |
Q4 2020 | $2,807,000 | +90.7% | 32,445 | +34.7% | 0.02% | +63.6% |
Q3 2020 | $1,472,000 | +46.9% | 24,087 | 0.0% | 0.01% | +37.5% |
Q2 2020 | $1,002,000 | +44.8% | 24,087 | 0.0% | 0.01% | +14.3% |
Q1 2020 | $692,000 | -60.2% | 24,087 | 0.0% | 0.01% | -46.2% |
Q4 2019 | $1,739,000 | -48.5% | 24,087 | 0.0% | 0.01% | -51.9% |
Q3 2019 | $3,379,000 | -27.6% | 24,087 | -5.5% | 0.03% | -28.9% |
Q2 2019 | $4,665,000 | -8.4% | 25,480 | -20.4% | 0.04% | -7.3% |
Q1 2019 | $5,091,000 | +41.9% | 32,011 | -14.5% | 0.04% | +36.7% |
Q4 2018 | $3,587,000 | -23.9% | 37,443 | +12.3% | 0.03% | -3.2% |
Q3 2018 | $4,711,000 | -6.1% | 33,350 | +4.1% | 0.03% | -6.1% |
Q2 2018 | $5,015,000 | -18.8% | 32,040 | -16.4% | 0.03% | +120.0% |
Q1 2018 | $6,175,000 | -1.9% | 38,338 | +0.3% | 0.02% | 0.0% |
Q4 2017 | $6,292,000 | +20.1% | 38,205 | -54.6% | 0.02% | +25.0% |
Q3 2017 | $5,238,000 | +14.3% | 84,088 | +46.2% | 0.01% | 0.0% |
Q2 2017 | $4,583,000 | -2.7% | 57,529 | -13.1% | 0.01% | -7.7% |
Q1 2017 | $4,709,000 | +15.3% | 66,227 | -17.2% | 0.01% | +8.3% |
Q4 2016 | $4,085,000 | +46.6% | 80,010 | +32.2% | 0.01% | +33.3% |
Q3 2016 | $2,786,000 | +25.9% | 60,509 | -12.3% | 0.01% | +28.6% |
Q1 2016 | $2,213,000 | -45.1% | 69,028 | -0.2% | 0.01% | -41.7% |
Q4 2015 | $4,032,000 | -8.5% | 69,160 | -33.6% | 0.01% | -14.3% |
Q3 2015 | $4,408,000 | +98.4% | 104,163 | +242.2% | 0.01% | +180.0% |
Q2 2015 | $2,222,000 | – | 30,441 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
RA Capital Management | 455,173 | $74,972,000 | 6.27% |
Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |